Observing the natural history of certain blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the natural history of monoclonal B cell lymphocytosis (MBL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), Waldenstrom macroglobulinemia (WM), and splenic marginal zone lymphoma (SMZL). It will collect blood, tissue samples, and imaging studies from patients to characterize clinical, biological, and molecular events related to disease stability and progression. Patients will be followed over time to gather data that could lead to the discovery of new treatment targets and a better understanding of these conditions.

Why it matters

Who can join: the full rules

-INCLUSION CRITERIA:

1. Diagnosis of CLL/SLL will be made according to the updated criteria of the NCI Working Group.

   * on treatment or previously treated
   * requiring or nearing first-line treatment

   OR

   Diagnosis of LPL/WM. LPL is defined as the presence of an intertrabecular pattern of bone marrow infiltration by small lymphocytes showing plasmacytoid/plasma cell differentiation. WM, comprising \>95% of LPL cases, describes the clinical syndrome of LPL associated with an IgM monoclonal gammopathy of any concentration. The remaining cases may be IgA, IgM, or non-secreting LPL. Immunophenotyping is required for diagnosis
2. Age greater than or equal to 18 years.
3. ECOG performance status of 0-2.
4. Able to comprehend the investigational nature of the protocol and provide informed consent

EXCLUSION CRITERIA:

1\. None

Where it's running

• National Institutes of Health Clinical Center
  Bethesda, Maryland, United States Recruiting

Study contacts

• Principal investigator: Adrian U Wiestner, M.D. — National Heart, Lung, and Blood Institute (NHLBI)
• Study coordinator: Yeseul Kim
• Email: yeseul.kim@nih.gov
• Phone: (240) 328-8992

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized exercise and nutrition program to reduce cancer-related fatigue

  This program will try a personalized exercise and diet plan to reduce fatigue for adults with indolent lymphomas (including CLL/SLL and follicular lymphoma).

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT06860880

• Pirtobrutinib combined with venetoclax and rituximab for Waldenström's macroglobulinemia

  This treatment tries combining pirtobrutinib, venetoclax, and rituximab in people newly diagnosed with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma to see if it controls the disease.

  Recruiting at 9 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 8 other locations · NCT07231952

• Using CAR T cells to treat certain types of B cell lymphomas

  This study is testing a new CAR T cell therapy to see if it can help adults with certain types of B cell lymphomas that haven't improved with other treatments.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06340737

• Oral AS-1763 treatment for patients with certain blood cancers

  This study is testing a new oral medication called AS-1763 to see if it can help patients with certain blood cancers who haven't had success with other treatments.

  Recruiting at 13 sites Phase 1 Carna Biosciences, Inc. · Orange, California and 12 other locations · NCT05602363

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Comparing venetoclax and rituximab to ibrutinib and rituximab for treating Waldenstrom's macroglobulinemia

  This study is testing whether a new combination of venetoclax and rituximab works better than the standard treatment of ibrutinib and rituximab for people with Waldenstrom's macroglobulinemia who haven't been treated before.

  Recruiting at 106 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 149 other locations · NCT04840602

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.